纳斯达克 · USD

Alpha Tau Medical Ltd. (DRTSW) 股票分析

Alpha Tau Medical Ltd.（DRTSW）是在纳斯达克上市的股票，以美元交易。

DRTSW

$4.17

+$0.25 (+6.38%)

2026年9月4日 · 收盘

这是一只衍生品——Alpha Tau Medical Ltd.（DRTS）普通股的认股权证。

发行人的基本面数据显示在发行人页面，而非本页。

查看DRTS →

价格走势

悬停查看每日收盘价。虚线表示区间起始价。

DRTSW 关键统计数据

数据截至2026年9月4日

交易

开盘价: $0.33
前收盘价: $3.92
当日波动区间: 3.86–4.28
52周波动区间: 3.86–4.28
成交量: 46.10K
Beta系数: 1.21

仅显示公司披露的指标。数据由Yahoo Finance通过yfinance提供。每日更新。

DRTSW 历年回报率

历年回报率根据每日收盘价计算。不完整年度以浅色显示并标有星号。

年份	回报率
2026 (不完整年度)	+1163.64%
2025 (不完整年度)	+0.00%

数据截至2026年9月4日。

关于Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

公司简介以英文显示。

访问官网 →

Alpha Tau Medical Ltd. (DRTSW) 股票分析

价格走势

DRTSW 关键统计数据

DRTSW 历年回报率

最新新闻

Alpha Tau to Participate in September Investor Conferences

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

关于Alpha Tau Medical Ltd.